Clinical Trials
9 trialsNCT06125795 2026-05-01
PROVIDENCE
AbbVie
Active not recruiting
NCT06101134 2026-04-09
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT05883956 2025-03-20
PREFER-HMA
Otsuka Australia Pharmaceutical Pty Ltd
Phase 3 Active not recruiting
NCT05284591 2024-10-01
MYLENE
iOMEDICO AG
Completed
NCT05115006 2022-06-30
A Study of Adjuvant Melanoma Stakeholder Treatment Preferences
Bristol-Myers Squibb
Completed
NCT02616692 2017-09-27
HCC Patient Preferences in Japan
Bayer
Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT00721981 2010-12-10
An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy
AstraZeneca
Terminated